Ms. Bruno brings over 25 years of experience in the life sciences industry, spanning biotechnology, medical device, and pharmaceutical drug development. She began her career at the bench in an analytical laboratory supporting the characterization of investigational products through pharmacokinetic profiling and pharmacodynamic endpoint assessment across clinical and non-clinical studies. Building on her scientific foundation, she transitioned into strategic Quality leadership, partnering with emerging and growth-stage biopharmaceutical companies to design, implement, and mature scalable, inspection-ready Quality frameworks aligned with global regulatory standards. Prior to joining Immuneering in February 2026, Ms. Bruno held Quality leadership roles at Entasis Therapeutics , Spyre Therapeutics , and Geron Corporation . Ms. Bruno holds a Graduate Certificate in Regulatory Affairs from Northeastern University, an M.S. in Biotechnology from Worcester State University, and a B.S. in Biology from Framingham State University.
Patrick Xin
Patrick Xin has served as Senior Director of Clinical Data Management since December 2025, leading the company’s clinical data strategy and execution across global programs to support high-quality regulatory filings, scientific presentations, and publications. Prior to joining Immuneering, Patrick served as Executive Director at Arcturus Therapeutics, leading integrated biometric data management and statistical programming functions, and as Director of the Clinical Research DataCore at NYU Langone Health.
Patrick holds an M.S. in Computer Science from New Jersey Institute of Technology, an M.A. in Biochemistry from City University of New York, and a B.S. in Pharmaceutical Science from Fudan University, China
Vinny Hayreh, MD
Vinny Hayreh, MD, is a physician executive with extensive experience in oncology clinical development, medical affairs, and pharmacovigilance across global pharmaceutical and biotechnology organizations. She currently serves as Immuneering’s Vice President of Clinical Development, leading oncology programs from early clinical development through late-stage trials. She is also the Founder and CEO of Hayreh LLC, a pharmaceutical and biotechnology consulting firm providing clinical strategy, medical monitoring, and pharmacovigilant support for oncology programs. Previously, she held senior leadership roles including Senior Medical Director at Janssen Pharmaceuticals (Johnson & Johnson), Clinical Trial Lead (Medical Director) at Bristol Myers Squibb, Global Medical Affairs Leader and Global Safety Physician at AstraZeneca, and Senior Manager in Global Safety and Medical Communications at Amgen. Vinny received her medical degree from Grace University and completed post-graduate training at the University of California, Los Angeles.
Loretta Sullivan, MD, MPH
Loretta Sullivan, MD, MPH, has dedicated her life to improving global health. Over the last decade, she has held clinical leadership roles within the biopharmaceutical industry, including Genentech/Roche, Lilly, Astellas, J&J, ALX Oncology and Clovis Oncology. Prior to joining industry, Dr. Sullivan worked as an epidemiologist with the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), and various non-governmental organizations in over 30 countries. Dr. Sullivan earned her undergraduate degree from Dartmouth College, her MPH in epidemiology at UCLA and her medical degree at the University of Colorado with an internal medicine residency at UCLA and hematology/oncology fellowship at Stanford. She is a veteran, having served in the U.S. Public Health Service, and she is fluent in five languages. Loretta lives in Denver, Colorado, with her husband and three sons. In her spare time, she plays USTA tennis and loves to ski.
Leah Neufeld
Ms. Neufeld has served as our Chief People Officer since October 2022. Prior to joining us, Ms. Neufeld served as Chief Human Resources Officer of Luzsana Biotechnology (“Luzsana”) from August 2021 to October 2022, where she, as part of the executive team, helped establish Luzsana globally as a subsidiary of Hengrui Medicines. Previously, she was the Vice President, People, at Prevail Therapeutics from September 2019 to August 2021, until its acquisition by Eli Lilly. Prior to that, from August 2015 through September 2019, Ms. Neufeld was the Head of Human Resources at Intercept Pharmaceuticals, and from January 2014 to July 2015 was the Global Head of Human Resources for NPS Pharma until it was acquired by Shire Pharmaceuticals. From April 2009 to January 2014, she held positions of increasing responsibility at Daiichi Sankyo Pharma Development, most recently serving as Director of Human Resources. Earlier in her career, from November 2002 to April 2009, Ms. Neufeld held various human resources positions at Johnson & Johnson, including Manager of Human Resources in the consumer division and its oncology company called Ortho Biotech. Ms. Neufeld earned a B.A. in psychology from the American University and an M.S. in career counseling and organization development from Johns Hopkins University.
Mallory Morales, CPA
Ms. Morales has served as our Senior Vice President of Finance, Chief Accounting Officer and Treasurer since February 2026, and previously served as Chief Accounting Officer and Treasurer since July 2023, Vice President, Finance and Treasurer from August 2022 to June 2023 and Vice President, Finance from May 2021 to July 2022. Prior to joining us, Ms. Morales served as Strategic Finance Business Partner at Gilead Sciences, Inc. (“Gilead”), a biopharmaceutical company, from October 2020 to May 2021, where she oversaw the integration of the research and development organization of Immunomedics, Inc. (“Immunomedics”) following its acquisition by Gilead in October 2020. From April 2018 to October 2020, she served as Director and Assistant Controller at Immunomedics, an antibody drug conjugate company, where she oversaw the annual operating budget, forecasting and business planning. From May 2014 to April 2018, Ms. Morales held roles of increasing seniority at L’Oréal S.A., a personal care company, most recently as Director of Finance and Global Brand Controller of the L’Oreal Professional Products Division, where she oversaw and managed all financial and accounting functions. Ms. Morales is a CPA and began her career as an auditor for Pricewaterhouse Coopers. She earned her B.S. in Accounting and Business with honors from the State University of New York at Albany.
Igor Matushansky, M.D., Ph.D.
Dr. Matushansky has served as our Chief Medical Officer since March 2025. Prior to joining Immuneering, Dr. Matushansky served as Chief Medical Officer at Sail Biomedicines, a Flagship Pioneering biotechnology company, from July 2023 to January 2025, where he built out and led the clinical/medical, translational, operational and regulatory functions. Prior to that, Dr. Matushansky was SVP and Global Head of Oncology Development at Ipsen S.A., a global specialty-care biopharmaceutical company, from July 2022 to June 2023, where, among other programs, he oversaw the completion of NAPOLI-3 leading to the approval of NALIRIFOX for first-line pancreatic cancer. Dr. Matushansky also served as Chief Medical Officer and Global Head of Research and Development at Hookipa Pharma Inc., a biopharmaceutical company, from April 2017 to July 2022, where he was responsible for bringing novel arenavirus technology from early preclinical research to clinical proof-of-concept. He also served as Global Head of Oncology Early Development at Daiichi Sankyo from November 2015 to April 2017, leading the company’s international research unit focused on early oncology therapeutic programs, and was Global Head at the Gene & Cell Therapy Unit and earlier the Global Clinical Program Head within the Oncology Translational Medicine Unit at Novartis from June 2012 to November 2015. Dr. Matushansky began his career in academia at the Columbia University Medical Center, where he founded and directed a sarcoma center and ran a laboratory focused on the molecular basis of sarcomas. Dr. Matushansky continues to dedicate time treating sarcoma patients as an attending physician. Dr. Matushansky earned his B.A. from Columbia University and his M.D. and a Ph.D. in molecular biology from Albert Einstein College of Medicine. Dr. Matushansky performed his internal medicine residency at New York Presbyterian Hospital/Weill Cornell Medical Center, and completed a fellowship in medical oncology and a post-doctoral research fellowship in cancer biology at the Memorial Sloan Kettering Cancer Center.
Laurie Keating, J.D.
Ms. Keating has served on our Board of Directors since March 2021. Ms. Keating previously served as the Executive Vice President, Chief Legal Officer and Secretary of Alnylam Pharmaceuticals, Inc., from March 2019 until September 2021, and also served as its Senior Vice President, General Counsel and Secretary from September 2014 until March 2019. From September 2004 until January 2014, she served as the Senior Vice President, General Counsel and Secretary of Millennium Pharmaceuticals, Inc., a wholly owned oncology-focused subsidiary of Takeda Pharmaceutical Company Limited since 2008, and was the founding Chief Executive Officer and a member of the board of directors of Hydra Biosciences. Since December 2021 Ms. Keating has served on and currently chairs the board of directors of a clinical-stage biopharmaceutical company, PepGen Inc. (Nasdaq: PEPG), where she is also a member of the Audit and Nominating and Corporate Governance committees. From November 2021 until the company was acquired by Merck in January 2023, she served on the board of directors of Imago BioSciences (Nasdaq: IMGO), and from 2005 until March 2022 she served on the board of directors of MassBIO, a non-profit organization. Ms. Keating earned her A.B. in economics from the University of California, Berkeley and her J.D. from the University of California, Hastings College of the Law.